DOCSLIB.ORG

Client List LATEST

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Client List LATEST Client number client name country area code client comments corporate number 1382 3 FHEA LAB AD GER SONER C11612 1017 3M MEDICAL DEPARTMENT USA ST PAUL 785 A.H. MARNE & CO LTD UK BRADFORD C11634 1781 ART JAPAN INC. JAP TOKYO 103 Applied Ananlytical Immagary Inc. 644 ABBOTT LABORATORIES LTD US ilILLINOIS Abbott Park C10042 1789 ACTIVE BIOTECH RESEARCH SWE LUND Lund Research Centre AB 1244 AGAN CHEMICAL ITA C10693 1245 AGOURON PHARMACEUTICALS INC. USA SAN DIEGO C10007 774 AGREVO UK LTD UK Now use 1849 Aventis CropScience 1302 AGRITECH UK LIMITED UK SELBOURNE C11646 619 AGRO KAHEAHO COMPANY LTD JAP TOKYO C10854 1773 AIR PRODUCTS AND CHEMICALS INC USA USA C10007 702 AJIMOMOTO CO INC JAP C10323 1946 AJIMOMOTO PHARMACEUTICALS EURO UK REDHILL EUROPE LTD 1043 AKED INTERVET NET C10211 1710 AKZO NOBEL SWE STENLUNGEUN C10210 254 ALBRIGHT & WILSON UK LIMITED UK HENLEY C11661 ALEEN LABORATORIES INC USA FORT WORTH C10663 1747 ALIZYME THERAPEUTICSLTD UK CAMBRIDGE C14475 ALLELEX BIO PHARMACEUTICALS CAN ONTARIO C14103 804 ALLERMAN UK C10903 2791 ALLERCENE LTD RAMAT ISRAEL 1725 ALLERGY THERAPEUTICS LTD UK WORTHING 635 ALMIRALL SPA BARCELONA C10320 1741 ALPHARMA AU NOR OSLO C23276 628 AMERICAN CYANAMID COMPANY USA C10016 1838 AMRAD OPERATIONS PTY LTD AUS RICHMOND C10135 1702 AMVAC CHEMICAL CORPORATIONUSA USA CITY OF CO City of COMMERCE, California C10814 1184 AMYLIN EUROPE LTD UK OXFORD C10020 1070 ANCARE NEW ZEALAND LTD NZ AUCKLAND 607 ANT. INTERNATIONAL LTD UK SUDBURY C11694 1622 ANTISEPTICA GmbH GER 1070 AORTECH EUROPE LTD UK LEEDS 1098 APHTON CORPORATION USA WOODLAND CITY C10916 1737 APOTEX RESEARCH INC. CAN ONTARIO C14502 1628 AQUAMARINE (LONDON) LTD UK HOUNSLOW 1711 ARIAD PHARMACEUTICALS INC USA MASS. C13170 663 ASAHI CHEMICAL IND. CO. LTD JAP SHIZUOKA-K C10346 1399 ASHLAND CHEMICL COMPANY USA Division of Ashland Inc, Ohio 127 AUTO PHARMA GER 2840 ASTACAROTENE AU SWE GUSTAVSEER 66 ASTRA ZENECA UK MACCLESFIELD 2889 ASTRAZENECA AB SWE 2890 ASTRAZENECA AB SWE MELADAL 1263 ASTRAZENECA R & D SWE LUND C10025 2423 ASTRAZENECA R & D CHARNWOOD UK LOUGHBOROUGH C10055 2430 ATHENA NEUROSCIENCES (USA) USA SAN FRANCISCO C17028 2808 AVECIA INC USA WILMINGTON 1803 AVECIA LEM UK CHESHIRE 1048 AVENTIS CROPSCIENCE UK LTD UK Agrevo UK - Rhone Paulenc Agriculture 1652 AVENTIS PASTEUR LTD CAN ONTARIO Pasteur Merioux Connought C10246 552 AVENTIS PHARMA FRA PARIS Formerly Hoescht Harton Rounel Franc C10131 1859 AVENTIS PHARMA AG GER 68 AVENTIS PHARMA LTD UK CREWE Formerly Rhone Poulenc Rorer C10246 1719 AVENTIS PHARMA RECHERCHE-DEVEL FRA ALFORTVILL Formerly Rhone Poulenc Secteur Pharma C10246 1609 AXIS GENETICS PLC UK BABRAHAM C11671 1879 AXXIMA PHARMACEUTICALS CO. LTD GER MUNICH 1736 ANIMEDICA WEST CHEMISCHE PRODU GER SENDEN-BOS 48308 Senden-Bosensell 800B.A.T (BRITISH AMERICAN TOBACCO ) UK SOUTHAMPTO British American Tobacco C12244 1742 BAKER PETROLITE UK LIVERPOOL Division of Baker Hughes Ltd 729 BASF AG GER LIMBURGERH C10928 1321 BASS BREWERIES UK BURTON ON TRENT C11677 1775 BASSETLAW HOSPITAL & COMMUNITY UK BASSETLAW 262 BAYER AG GER WUPPERTAL C10034 1820 BAYER CORPORATION USA CLAYTON 1670 BAYER PHARMA FRA PUTEAUX C10034 48 BAYER PLC UK BURY ST EDMUNDS Animal Health Business Group C10034 1754 BAYER YAKUHIN LTD JAP OSAKA C14515 1680 BESPAK PLC UK KINGS LYNN 1792 BEST WORLD TRADING LTD SKO SEOUL 1734 BIBRA INTERNATIONAL UK CARSHALTON 1668 BINDING SITE LTD UK BIRMINGHAM The Binding Site Ltd 1136 BIOGEN INC USA CAMBRIDGE C10042 1748 BIONET INVESTMENT HOLDING GmbH GER MUNCHEN 1638 BIONOR AS NOR SKIEN 1847 BIOPHORETIC THERAPEUTIC SYSTEM USE FRAMINGHAM 1304 BIORELIANCE LTD UK STIRLING Formerly MA Bioservices C11969 1833 BIOTA SCIENTIFIC MANAGEMENT PTY LTD AUS MELBOURNE 1900 BIOTIE THERAPIES LTD FIN TURKU 1882 BIOTOX USA RICHMOND 1896 BIOVECTOR THERAPEUTICS FRA LASEGE 1776 BODYWISE UK BRISTOL 979 BOEHRINGER INGEL HEIM (UK) LTD UK BRACKNELL C10046 1839 BOEHRINGER INGELHEIM PHARM INC. USA RIDGEFIELD 1813 BOEHRINGER INGELHEIM PHARMA KG GER BIBERECH/R Biberech an der Riss 806 BOEHRINGER INGELHEIM VETMEDICA GER INGELHEIM C10046 418 BOEHRING ER INGELHEIM GER ? Duplicate of 0059 ? C10046 1341 BORAX EUROPE LTDUKWIDNES Formerly Borax Consolidated Ltd C12240 1272 BRACCO ITA MILAN C10051 1183 BRACCO RESEARCH S.A SWI CAROUGE GE C10051 1092 BRAUN MELSUNGEN AG GER C10353 1254 BRESTA UMWELTSER SERVICE GER C11700 1274 BRISTOL MYERS SQUIBB COMPANY USA PRINCETON C10052 1340 BRISTOL MYERS SQUIBB COMPANY USE SYRACUSE C10052 1688 BRISTOL MYERS SQUIBB COMPANY USA WALLINGFOR Pharmaceutical Division C10052 1560 BRISTOL MYERS SQUIBB PHARMACEU UK HOUNSLOW C10052 868 BRITISH BIOTECH PLC UK OXFORD C10053 1735 BRITISH SUGAR TECHNICAL CENTRE UK NOR 382 BYK GULDEN GER KONSTANE C10331 1677 C F F I AGRO FRA GENNEVILLI Department Homologtions et Reglementati C10952 1769 CALYDON USA SUNNYVALE 1348 CAMBRIDGE ANTIBODY TECHNOLOGY UK CAMBRIDGE C11722 1726 CAMURUS AS SWE LUND 1789 CANDIDA MEDICAL BV NET ROTTERDAM 1986 CANDIDA MEDICAL BV FRA PARIS 489 CANTAB PHARMACEUTICAL RESEARCH UK CAMBRIDGE Please use 1250 C10382 1250 CANTAB PHARMACEUTICAL PLC UK CAMBRIDGE C10382 1698 CASTLE HILL HOSPITAL UK COTTINGHAM 1818 CATO RESEARCH CANADA CAN SAINT-LAUR 1398 CELGENE CORPORATION USA WARREN C10059 1084 CELLTECH THERAPEUTICS LTD UK SLOUGH C10388 1751 CENTRAL SCIENCE LABORATORY UK YORK 1678 CENTRE DE PRIMATOLOGIE FRA STRASBOURG 1360 CENTRE FOR INDOOR AIR RESEARCH USA LINTHICUM C10731 1277 CEPHALON INC. UK GUILDFORD C10062 1644 VERNALIS RESEARCH LTD UK WOKINGHAM C14381 1614 CERESTAR USA INC. USA HAMMOND IN C14511 1503 CHANELLE PHARMACEUTICALS MAN. EIRE LOUGHREY C11736 1778 CHEMCOLOUR INDUSTRIES (NZ) LTD NZ AUCKLAND 1807 CHEMICAL MANUFACTURERS ASSOCN. USA ARLINGTON Also known as CMA 1024 CHEMISCHE FABRIK STOCKHAUSEN GER KREFELD 1 C12249 1669 CHIMAC-AGRIPHAR BEL 1363 CHIRON CORPORATION USA EMERYVILLE C10065 1193 CHIROSCIENCE LIMITED UK CAMBRIDGE C10735 1869 CHLORINATED PARAFFINS IND. ASS. USA WASHINGTON (CPIA) 1634 CHUGAI PHARMA EUROPE LTD UK LONDON C10066 380 CIBA GEIGY SWI BASLE C10067 1436 CIBA SPECIALITY CHEMICALS INC. SWI BASLE Formerly GRENZACH, GERMANY C10067 1665 CIBA VISION SWI BASLE C10068 1791 CIRCA DIA NET DEN NAAG C14355 1433 CLARIANT (FRANCE) S.A FRA PARIS Formerly SOCIETY FRANCAISE HOECHST C12250 1451 CLARIANT (SWITZERLAND) LTD SWI MUTTENZ Formerly CLARIANT INTERNATIIONAL LTD C12250 1164 CLINICAL TRIALS LTD UK YORK C10075 1551 COBRA THERAPEUTICS LIMITED UK KEELE 3/1/97 Formerly THEREXSYS until MAR 98. C11336 1215 COCENSYS USA C10076 1666 COLLATERAL THERAPEUTICS USA SAN DIEGO 1692 COLQUIMICA POR VALONGO Industria Nacional de Colas SA 1695 CONSULTANTS ITA Awaiting full title/address …Marion 1653 CONVATEC LIMITED UK DEESIDE Advanced Technology Department C10401 1230 CORTECS (UK) LIMITED UK DEESIDE Deeside Industrial Park C10406 1761 CORTENDO AB SWE MALMO Formerly at Vastra Frolunda C14514 1757 COVANCE CENTRAL DIAGNOSTICS IN USA RENO 1492 COVANCE CENTRAL LABORATORY SER SWI GENEVA Formerly Corning Scicor SA C10084 1091 COVANCE CLINICAL RESEARCH UNIT UK LEEDS Formerly GHBA Clinic 742 COVANCE CLINICAL and PERIAPPO UK MAIDENHEAD Formerly Corning GH Besselaar C10316 155 COVANCE LABORATORIES INC. USA VIENNA Fornerly Corning Hazleton Systems 1194 COVANCE LABORATORIES LTD UK HARROGATE Formerly Corning Hazleton Europe 1872 CRAY VALLEY IBERICA SPA BARCELONA 11 CREMER & WARNER UK C11766 1674 CULTOR FOOD SCIENCE UK REDHILL C12778 16 CYANAMID AGRICULTURE LTD UK GOSPORT Formerly Cyanamid UK C10088 1531 CYANAMID AGRO FRA TASSIN LA Formerly Agrishell …1112 C10088 1346 CYANAMID FORSCHUNG GER SCHWABENHE C10088 1611 CeNes LTD UK CAMBRIDGE HQ at Histon, Cambridge 13/7/98 C11731 1870 CELLPEP s.a FRA 1819 CuMEDICA Limited UK MANCHESTER The University of Manchester 783 DAICHI PHARMA JAP C10091 1689 DANISH TOXICOLOGY CENTRE DEN HORSHOLM 1650 DEGUSSA AG GER HANAU C12638 1814 DENYKEM UK OSSETT 1646 DERA Head Office UK FARMBOROUG 1841 DEUTSCHE BAHN AG GER BERLIN 1357 DIAMED GER C11782 1641 DIAMYD MEDICAL AB SWE STOCKHOLM Formerly Biosyn Holdings AB 14.01.99 C14472 999 DISCOUNT 1749 DOMPE SPA ITA MILAN 295 DOW AGROSCIENCES UK WANTAGE Formerly Dowelanco Limited C10984 1428 DR F KOHLER CHEMIE GMBH GER ALSBACH-HA C11325 1808 DR WESSLING LABORATORIEN Gmbh GER BOCHUM 1863 DRINKING WATER INSPECTORATE UK LONDON 1758 DSM RESINS NET ZWOLLE 269 DUPONT SWI C10098 550 DUPONT AGRICULTURAL PRODUCTS USA Formerly Dupont De Nemours and Co C10098 1378 DUPONT DE NEMOURS FRA PARIS C10098 1844 DUPONT ITALIANA ITA MONZESE 1482 DUPONT PHARMACEUTICALS COMPANY USA WILMINGTON Formerly Dupont Merck Pharmaceuticals C10098 1498 DUPONT PHARMACEUTICALS COMPANY USA NEWARK, DE Formerly Dupont Merck C10098 1116 EISAI COMPANY LIMITED JAP GIFU 501-6 C10101 726 EISAI EUROPE LTD UK LONDON C10101 1282 ELAN CORPORATION PLC EIRE ATHLONE C10102 1825 ELAN PHARMACEUTICALS USA SAN FRANSI 154 ELF ACQUTAINE FRA C10992 1607 ELF ATOCHEM AGRI BV FRA PLAISIR AG C10992 514 ELF ATOCHEM AGRI SA FRA LA DEFENSE IC C10992 1496 ELI LILLY & Co LTD USA INDIANAPOL Lilly Research Laboratories C10103 1691 ELI LILLY & Co LTD USA GREENFIELD Lilly Research Laboratories C10103 689 ELI LILLY & CO LTD, LILLY RESE UK WINDLESHAM Formerly Lilly Research Centre Ltd C10103 1448 EMS DEUTSCHLAND GER MEERSBURG 1255 ERIAL ALLERGEN GER C11820 1727 ESPERION THERAPEUTICS LTD USA MICHIGAN C14457 1712 ESSENTIAL NUTRITION LTD UK BROUGH 1787 EU COPPER TASK FORCE UK HARROGATE 1876 FAIRFAX DENTAL LTD UK LONDON 1823 FAMILY HEALTH INTERNATIONAL USA Research Triangle Park, N Carolina 1657 FERRING NET C10446 1475 FERRING A/S DEN VANLOSE C10446 595 FERRING AB SWE MALMO C10446 1660 FINNEGAN, HENDERSON, FARABOW USA WASHINGTON
Load more

Recommended publications
  • Chief Executive Officer Graham Baker
    OVERVIEW OUR BUSINESS OPERATIONAL FINANCIAL RISK GOVERNANCE ACCOUNTS 48 & MARKETPLACE REVIEW REVIEW OUR BOARD OF DIRECTORS ROBERTO QUARTA (67) OLIVIER BOHUON (58) GRAHAM BAKER (48) CHAIRMAN CHIEF EXECUTIVE OFFICER CHIEF FINANCIAL OFFICER Joined the Board in December 2013 and Joined the Board and was appointed Chief -RLQLQJWKH%RDUGDV&KLHI)LQDQFLDO2I²FHULQ appointed Chairman following election by ([HFXWLYH2I²FHULQ$SULO+HUHVLJQHGDV March 2017. shareholders at the April 2014 Annual General a Member of the Nomination & Governance Meeting. He was also appointed Chairman of &RPPLWWHHRQ)HEUXDU\ CAREER AND EXPERIENCE the Nomination & Governance Committee and Graham holds an MA degree in Economics from a Member of the Remuneration Committee on CAREER AND EXPERIENCE Cambridge University and qualified as a Chartered that day. Olivier holds a doctorate in Pharmacy from the Accountant and Chartered Tax Advisor with Arthur University of Paris and an MBA from HEC, Paris. Andersen. In 1995, he joined AstraZeneca PLC where CAREER AND EXPERIENCE He started his career in Morocco with Roussel Uclaf he worked for 20 years, holding multiple senior roles, Roberto is a graduate and a former Trustee of the S.A. and then, with the same company, held a number including Vice President, Finance, International (2013- College of the Holy Cross, Worcester (MA), US. of positions in the Middle East with increasing levels of 2015) with responsibility for all emerging markets, He started his career as a manager trainee at David responsibility. He joined Abbott in Chicago as head of Vice President, Global Financial Services (2011-2013) Gessner Ltd, before moving on to Worcester Controls their anti-infective franchise with Abbott International and Vice President Finance & Chief Financial Officer, Corporation and then BTR plc, where he was a before becoming Pharmaceutical General Manager North America (2008-10).
    [Show full text]
  • PCT Gazette, Weekly Issue No. 29, 1998
    29/1998 23 Jul/juil 1998 PCT Gazette - Section I - Gazette du PCT 11497 SECTION I PUBLISHED INTERNATIONAL APPLICATIONS DEMANDES INTERNATIONALES PUBLIÉES 6 (11) WO 98/31208 (13) A1 (43) 23 Jul/juil 1998 (23.07.1998) (51) A01J 7/00 // 5/017, A01K 1/12, H05K 5/00 (51)6 A01C 5/06 (21) PCT/GB98/00026 (54) A DEVICE FOR A MILKING STALL DISPOSITIF DESTINE A UNE SALLE DE (54) PLANTING UNIT TRAITE (22) 14 Jan/jan 1998 (14.01.1998) UNITE DE PLANTATION (25) en (26) en (71) ALFA LAVAL AGRI AB [SE/SE]; P.O. Box 39, (71, 72) BAUGHER, Roger, D. [US/US]; P.O. Box S–147 21 Tumba (SE). 79–A, McClure, IL 62957 (US). BAUGHER, Gar- (for all designated States except / pour tous les États (31) 9700754.6 (32) 15 Jan/jan 1997 (33) GB reth, D. [US/US]; P.O. Box 79–A, McClure, IL désignés sauf US) (15.01.1997) 62957 (US). (72, 75) KULLBERG, Marianne, Kristina, (43) 23 Jul/juil 1998 (23.07.1998) (74) MATTHEWS, Stephen, R.; Haverstock, Garrett & Åkesdotter [SE/SE]; Östmarksgatan 36, S–123 6 Roberts, Suite 1610, 611 Olive Street, St. Louis, 42 Farsta (SE). GUSTAFSON, Percy, Birger, (51) A01B 35/24 MO 63101 (US). Kenneth [SE/SE]; Björknäsvägen 25, S–151 37 Södertälje (SE). (54) TINE FOR MOUNTING ON SOIL–WORKING (81) AL AM AT AU AZ BA BB BG BR BY CA CH IMPLEMENT CN CU CZ DE DK EE ES FI GB GE GH HU IL (74) BERGLUND, Stefan et al. / etc.; Bjerkéns DENT S’ADAPTANT SUR UN ENGIN DE TRA- IS JP KE KG KP KR KZ LC LK LR LS LT LU Patentbyrå KB, Östermalmsgatan 58, S–114 50 VAIL DU SOL LV MD MG MK MN MW MX NO NZ PL PT RO Stockholm (SE).
    [Show full text]
  • Abstract Book 2014.Indd
    JOURNAL OF PSYCHOPHARMACOLOGY SUPPLEMENT TO VOLUME 28, ISSUE 8, AUGUST 2014 These papers were presented at the Summer Meeting of the BRITISH ASSOCIATION FOR PSYCHOPHARMACOLOGY 20 – 23 July, Cambridge, UK Indemnity The scientific material presented at this meeting reflects the opinions of the contributing authors and speakers. The British Association for Psychopharmacology accepts no responsibility for the contents of the verbal or any published proceedings of this meeting. All contributors completed a Declaration of Interests form when submitting their abstract BAP Office 36 Cambridge Place Hills Road Cambridge CB2 1NS www.bap.org.uk Aii CONTENTS Abstract Book 2014 Abstracts begin on page: SYMPOSIUM 1 Psycho-immunology (S01-S04) A1 SYMPOSIUM 2 Predictors of clinical response in depression (S05-S08) A2 SYMPOSIUM 3 ADHD and obesity: Overlapping neurobiology and development of pharmacological treatments (S09-S12) A3 SYMPOSIUM 4 Cannabinoids in psychiatry: Current understanding and future treatments (S13-S16) A4 SYMPOSIUM 5 Chickens and Eggs: Separating cause and effect in drug addiction (S17-S20) A6 SYMPOSIUM 6 Genetic pathways in psychosis: the road to new treatments? (S21-S24) A7 SYMPOSIUM 7 The adolescent brain – A key stage in the development of psychiatric disorders? (S25-S28) A8 SYMPOSIUM 8 Tobacco addiction in schizophrenia: a translational investigation (S29-S32) A9 SYMPOSIUM 9 Dopamine, impulse control disorders and Parkinson’s disease (S33-S36) A11 POSTERS Cognition (Animals) (MA01-MA14) A12 Drug Dependence (Human) (MB01-MB28)
    [Show full text]
  • Biotechnology and the Economics of Discovery in the Pharmaceutical Industry
    BIOTECHNOLOGY AND THE ECONOMICS OF DISCOVERY IN THE PHARMACEUTICAL INDUSTRY HELEN SIMPSON Office of Health Economics 12 Whitehall London SWlA 2DY ©October 1998. Office of Health Economics. Price £7.50 ISBN 1 899040 60 9 Printed by BSC Print Ltd, London. About the Author Helen Simpson is currently a researc~ economist at the Institute for Fiscal Studies and was formerly an economist at the Department of Trade and Industry. However, the opinions expressed here are her own and do not necessarily reflect the views of the IFS or of DTI officials or ministers. Acknowledgements This paper has been developed from my MPhil Economics thesis Scientist Entrepreneurs and the Finance of Biotech Companies. I would like to thank Margaret Meyer, Paul David and Gervas Huxley for their valuable suggestions. I am particularly grateful to Hannah Kettler and Jon Sussex for their advice and editorial inputs to the paper. My thanks also go to Adrian Towse and members of the OHE Editorial Board for their comments, and to the following individuals who gave me their insights into the pharmaceutical industry: Dr Trevor Jones, Director General, ABPI; Dr Janet Dewdney, Chairman, Adprotech; Dr Clive Halliday, Head of Global External Scientific Affairs, Glaxo Wellcome; Mr Alan Galloway, Head of Research Administration, Dr Nick Scott-Ram, Director of Corporate Affairs, and Dr Philip Huxley, all of British Biotech; Christine Soden, Finance Director, Chiroscience; Ian Smith, Lehman Brothers Pharmaceutical Research; and Paul Murray, 31. The Office of Health Economics Terms of Reference The Office of Health Economics (OHE) was founded in 1962. Its terms of reference are to: • commission and undertake research on the economics of health and health care; • collect and analyse health and health care data from the UK and other countries; • disseminate the results of this work and stimulate discussion of them and their policy implications.
    [Show full text]
  • Specialists in Small Molecule Drug Development
    Specialists in Small Molecule Drug Development Dr Stephen Parker, Chairman Dr Tim Mitchell, CEO & Co-Founder Dr John Reader, CSO & Co-Founder Final Results for the Year Ending 30 June 2019 October 2019 www.sareum.co.uk Disclaimer The information contained in this document (“Presentation”) is directed at (i) members or creditors of a corporate body within the meaning of Article 43 of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005, as amended ("Order"), (ii) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Order, or (iii) those persons to whom it can otherwise be distributed without contravention of article 21 of the Financial Services and Markets Act 2000 (“FISMA”) or to whom it can lawfully be distributed. This Presentation has been prepared by Sareum Holdings PLC (“Company”) and provided to you for information purposes only. This Presentation is not an invitation or inducement to engage in an investment activity for the purposes of FISMA. This Presentation has not been approved by an Authorised Person (as defined in s31 FISMA), as would be required for financial promotions under s21 FISMA and, for the avoidance of doubt, is not a financial promotion for the purposes of FISMA. If, contrary to the above, this Presentation is deemed to be a financial promotion for the purposes of FISMA, the Company relies on the exemptions set out in Articles 19, 43, 59 and 69 of the Order, which exempts companies admitted to trading on relevant markets making certain communications. Please note that any indication of past performance should not be relied upon as a guide to future performance.
    [Show full text]
  • Programme 10.00 Registration 10.20 Welcome from the Host
    Leadership Seminar: Respiratory and Inflammatory Diseases 22 September 2016 Penningtons Manches, 125 Wood Street, London EC2V 7AW Sponsored by Hosted by Programme 10.00 Registration 10.20 Welcome from the Host 10.30 Introduction Adrian Dawkes, PharmaVentures 10.45 Keynote presentations and discussion on unmet clinical needs including: 10.45 Symptoms vs Disease Modification Approach Lars Larson, TranScrip 11.05 Prospects for the prevention and treatment of respiratory virus-induced exacerbations in asthma and COPD Garth Rapeport, Pulmocide 11.25 Eosinophil depletion with benralizumab (anti-IL-5R) for the management of Severe Asthma and Chronic Obstructive Pulmonary Disease (COPD) Suzanne Cohen, MedImmune 11.45 Breath Biopsy - Breath Volatile Organic Compounds (VOCs) as Markers for Respiratory Disease Billy Boyle, Owlstone Medical 12.05 Panel discussion and Q&A 12.30 Lunch and networking 14.00 Data Protection and Liability in Respiratory Connected Devices Oliver Bett, Penningtons Manches 14.20 Adaptive Design in Respiratory Clinical Trials – A Sponsor’s Business Case Alethea Wieland, Scope International 14.40 Development of Immunoassays and Point-of-Care Tests for the Measurement of Active Protease Biomarkers of Chronic Respiratory Disease David Ribeiro, ProAxsis 15.00 Aiming for the Lungs - Formulation Strategies for Delivery of Inhaled Biologics Charlotte Yates, Vectura 15.30 Tea, coffee and networking 16.00 Innovative therapeutic options 16.00 The Development of an IL-17BR therapeutic antibody for the treatment of Asthma and IPF David Matthews, MRC Technology 16.20 Mycobacterium Tuberculosis Derived Peptide as a Disease Modifying Therapy for Asthma Nicky Cooper, Peptinnovate 16.40 Closing Remarks and Drinks Reception 18.00 Event closes Speaker Profiles Oliver Bett Associate, Penningtons Manches Oliver is an associate in our IP, IT and commercial team of Penningtons Manches, based in the London office.
    [Show full text]
  • The Joint Pharmacokinetics UK 2005 and Rosenön Meeting
    Welcome to the joint Pharmacokinetics UK 2005 and Rosenön Meeting Wednesday 23rd – Friday 25th November, 2005 De Vere Grand Hotel King’s Road Brighton BN1 2FW Programme and Abstract Book Published with the support of John Wiley & Sons Ltd, publishers of the journal BIOPHARMACEUTICS AND DRUG DISPOSITION rd Wednesday 23 November 12.30 Arrival, Coffee & Buffet Welcome & Session 1: Pharmacogenetics on PK/PD 13:50 Welcome (Steve Toon & Amin Rostami) 14:00 Introduction to the First Session: Geoff Tucker and Margareta Hammarlund-Udenaes 14:05 Geoff Tucker Pharmacogenetics on PKPD – expectations and reality 14:35 Duncan McHale Applications of Pharmacogenomics to the drug discovery and development pipeline 15:05 Leif Bertilsson Interethnic differences in drug disposition 15.30 Coffee break Viewing Posters & Exhibitions 16:00 Munir Pirmohamed Pharmacogenetics of adverse drug reactions Simulations as a tool to assess the propagation of genetic polymorphisms in drug Gemma Dickinson 16:20 metabolising enzymes into PK and PD outcomes 16:40 Marja-Liisa Dahl Pharmacogenetics in PK and PD of warfarin 17:30 Break 18:30 Poster Session – Free Bar 20:30 Dinner th Thursday 24 November Session 2: Microdosing in Drug Development 09:00 Introduction to Second Session: Anders Grahnen and Steve Toon 09:10 Colin Garner Human PK studies on microdoses of drugs - scientific and regulatory perspectives Seeing through the MIST: abundance versus percentage commentary on metabolites 09:50 Dennis Smith safety testing 10:30 Coffee break Viewing Posters & Exhibitions 11:00
    [Show full text]
  • United States Securities and Exchange Commission Form 10-K Shire Pharmaceuticals Group
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ፤ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 1999 អ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 0-29630 SHIRE PHARMACEUTICALS GROUP PLC (Exact name of registrant as specified in its charter) England and Wales (State or other jurisdiction (I.R.S. Employer of incorporation or organization) Identification No.) N.A. East Anton, Andover, Hampshire SP10 5RG England (Address of principal executive offices) (Zip Code) 44 1264 333455 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of exchange on which registered American Depository Shares, each representing Nasdaq National Market 3 Ordinary Shares, 5 pence nominal value per share Securities registered pursuant to Section 12(g) of the Act: None (Title of class) Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ፤ No អ Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the Registrant's knowledge, in definitive proxy or information statements incorporated by reference to Part III of this Form 10-K or any amendment to this Form 10-K.
    [Show full text]
  • National Lipid Association Annual Summary of Clinical Lipidology 2016 Disclosures Dr. Harold E. Bays: Dr. Bays Discloses That He
    National Lipid Association Annual Summary of Clinical Lipidology 2016 Disclosures Dr. Harold E. Bays: Dr. Bays discloses that he has received research grants from Arena Pharmaceuticals, Boehringer Ingelheim, Cargill Inc., GlaxoSmithKline, Novo Nordisk, Orexigen Therapeutics, Shionogi, Takeda, Stratum Nutrition, California Raisin Board, Esperion, Essentialis, Forest, Gilead Sciences Inc., Given, Hoffman-LaRoche, Home Access, Novartis, Omthera, Pfizer, Trygg Pharmaceuticals, TWI Bio, Xoma, Ardea Inc., High Point Pharmaceuticals LLC, Micropharma Limited, TransTech Pharma Inc., TIMI, Pozen, Regeneron, and Elcelyx. He further discloses that he has received honoraria/research grants from Amarin, Amgen, AstraZeneca, Bristol-Myers Squibb, Catabasis, Daiichi-Sankyo Inc., Eisai, Merck & Co, VIVUS, Zeomedex, and WPU. Dr. Peter H. Jones: Dr. Jones has received consulting or speaker honoraria from Merck and Co., Amgen, and Sanofi-Aventis/Regeneron. Dr. W. Virgil Brown: Dr. Brown is the editor of the Journal of Clinical Lipidology and further discloses that he has received consulting fees/honoraria from Akcea, Esperion, Regeneron, Amgen, Genzyme, Pfizer Inc., Merck and Co, GlaxoSmithKline, Medtelligence, and Vindico. Dr. Terry A. Jacobson: Dr. Jacobson has received consulting fees from Merck and Co., Amarin, Amgen, AstraZeneca, and Regeneron/Sanofi-Aventis. Dr. Karen E. Aspry: Dr. Aspry has no disclosures to report. Dr. Christie M. Ballantyne: Dr. Ballantyne has received research grants from Abbott Diagnostics, Amarin, Amgen, Eli Lilly, Esperion, ISIS Pharmaceuticals, Novartis Pharmaceuticals, Pfizer, Otsuka, Regeneron, Roche Diagnostic, Sanofi-Synthelabo, and Takeda Pharmaceuticals. He has also received consulting fees from Abbott Diagnostics, Amarin, Amgen, AstraZeneca, Eli Lilly, Esperion, Genzyme, ISIS Pharmaceuticals, Matinas BioPharma Inc., Merck and Co., Novartis Pharmaceuticals, Pfizer, Regeneron, Roche, and Sanofi-Synthelabo.
    [Show full text]
  • Drug Discovery Chemistry
    Save up to $200! Final Agenda Register by February 23 COVER CHI’s 13th Annual CONFERENCE AT-A-GLANCE PLENARY KEYNOTES SHORT COURSES Drug Discovery AGENDA Plenary April 3-4 Conferences »» Protein-Protein Interactions Keynotes »» Inflammation»&»Autoimmune» Inhibitors Chemistry »» Kinase»Inhibitor»Chemistry Optimizing Small Molecules for Tomorrow's Therapeutics »» GPCR-Targeted Drug Design »» Fragment-Based»Drug» Activity-Based April 2-6, 2018 | San Diego, CA | Hilton San Diego Bayfront Discovery Proteomics: April 4-5 Conferences Protein and »» Ubiquitin»Proteasome»System» Ligand Discovery Inhibitors on a Global Scale CONFERENCE PROGRAMS »» Small»Molecules»for»Cancer» Benjamin F. Cravatt, Immunotherapy PhD, Professor and APRIL 3-4 APRIL 4-5 APRIL 6 Co-Chair, Department »» Macrocyclics»&»Constrained» of Molecular Peptides Medicine, The Protein-Protein Ubiquitin Proteasome Biophysical Approaches »» Targeting»Complex» Scripps Research Membrane»Proteins Institute Interactions System Inhibitors for Drug Discovery April 6 Symposia »» Biophysical»Approaches»for» Lead Optimization Inflammation & Small Molecules for Drug»Discovery for Drug Metabolism Autoimmune Inhibitors Cancer Immunotherapy »» Lead»Optimization»for»Drug» & Safety Metabolism»&»Safety » Targeting Ras » Blood-Brain»Penetrant» Kinase Inhibitor Macrocyclics & Blood-Brain Inhibitors and MYC for the Treatment of Chemistry Constrained Peptides Penetrant Inhibitors HOTEL & TRAVEL Cancer Stephen Fesik, SPONSORSHIP PhD, Professor GCPR-Targeted Targeting Complex Plus Short Courses & EXHIBIT
    [Show full text]
  • 2019 Analyst Day
    2019 Analyst Day March 12, 2019 NASDAQ: LGND 2 Safe Harbor Statement The following presentation contains forward-looking statements by Ligand and its partners that involve risks and uncertainties and reflect Ligand's and it’s partners’ judgment as of the date of this presentation. Words such as “plans,” “believes,” “expects,” “projects,” “could,” “anticipates,” and “will,” and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, without limitation, financial projections, expectations regarding research and development programs, potential uses of capital, including any potential dividend or share repurchase program, and the timing of the initiation or compilation of preclinical studies and clinical trials by Ligand and its partners. Actual events or results may differ from Ligand’s expectations due to risks and uncertainties inherit in Ligand’s business, including: Ligand has wide discretion on its use of capital and may choose not to engage in any share repurchases, declare any dividends or pursue acquisitions or internal develop programs; Ligand and its partners may not be able to timely or successfully advance any product(s) in its internal or partnered pipeline;, drug development program benefits may not be realized; Ligand will achieve its guidance in 2019 or thereafter; third party research summarized herein may not be correct or complete; Kyprolis®, EVOMELA® and Zulresso™ may not perform as expected, Ligand relies on collaborative partners for milestone and royalty payments,
    [Show full text]
  • Executive Profile: Genzyme's CEO on Dark Times, Transition and the Long
    June 15th 2015 scripintelligence.com Executive profile: Genzyme’s CEO on dark times, transition and the long view David Meeker, CEO of Sanofi company Genzyme, recently found himself hustling back to Genzyme’s Kendall Square offices from a nearby meeting to talk to Scrip’s editor Eleanor Malone about the challenges and opportunities he has encountered in his varied career. In the first of a two-part series, he discusses his experiences in the company that he joined in 1994, and expounds upon issues faced by the industry as a whole. Eleanor Malone: Genzyme went through some dark times before the Sanofi acquisition with the manufacturing issues that led to shortages of enzyme replacement therapies. What lessons did you draw from those difficulties? David Meeker: You are absolutely correct; they were incredibly painful, dark moments. We failed to deliver on the implicit promise David Meeker addresses employees at of ensuring that patients can access the Genzyme’s HQ following a torch relay connecting the company’s sites near Boston medicines that they need. I think we learned to mark International Rare Diseases Day many lessons. On a very tactical level we learned about the lead time that it takes to bring biologic manufacturing up – we realised it right for the patient, given the limitations Many acquisitions destroy value, and a lot too late that we were not going to be at an we had. We were short of product so we had of the destruction happens when people adequate capacity and by the time we started to focus on how to manage the distribution leave: you have the products but you lose to build, even though it was several years of that product in a way which was most the know-how and the critical talent that ahead of when we ran out of medicine, we equitable.
    [Show full text]